首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SCGB3A1 |
| Uniprot No | Q96QR1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-104aa |
| 氨基酸序列 | MKLAALLGLC VALSCSSAAA FLVGSAKPVA QPVAALESAA EAGAGTLANP LGTLNPLKLL LSSLGIPVNH LIEGSQKCVA ELGPQAVGAV KALKALLGAL TVFG |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SCGB3A1重组蛋白的3篇参考文献(虚构示例，仅供格式参考)：
1. **文献名称**：*Recombinant SCGB3A1 inhibits lung inflammation in murine asthma models*
**作者**：Zhang Y, et al.
**摘要**：研究通过大肠杆菌表达系统制备重组SCGB3A1蛋白，发现其在小鼠哮喘模型中显著抑制嗜酸性粒细胞浸润和Th2细胞因子分泌，提示其抗炎潜力。
2. **文献名称**：*Expression and functional characterization of human SCGB3A1 in airway epithelial cells*
**作者**：Tanaka K, et al.
**摘要**：利用哺乳动物细胞表达重组SCGB3A1.证实其通过调节MAPK通路抑制呼吸道病原体诱导的黏液过度分泌，为慢性阻塞性肺病治疗提供新靶点。
3. **文献名称**：*SCGB3A1 recombinant protein attenuates tumor growth via anti-angiogenesis in lung adenocarcinoma*
**作者**：Wang X, et al.
**摘要**：体外实验表明，重组SCGB3A1通过下调VEGF信号通路抑制肺癌细胞诱导的血管生成，提示其作为肿瘤抑制蛋白的潜在应用。
(注：以上文献信息为模拟示例，实际研究中请通过PubMed或学术数据库检索真实文献。)
SCGB3A1 (Secretoglobin Family 3A Member 1) is a small secreted protein belonging to the secretoglobin superfamily, characterized by compact dimeric structures stabilized by disulfide bonds. Initially identified in the respiratory tract, SCGB3A1 is predominantly expressed in epithelial cells of the lung, uterus, and placenta, with emerging roles in mucosal immunity, inflammation regulation, and tissue repair. Its expression is modulated by hormonal signals and environmental stressors, suggesting involvement in both developmental and pathological processes.
Functionally, SCGB3A1 exhibits anti-inflammatory and anti-fibrotic properties, particularly in pulmonary contexts. Studies highlight its ability to suppress pro-inflammatory cytokines (e.g., IL-6. TNF-α) and inhibit TGF-β1-driven fibroblast activation, positioning it as a potential therapeutic target for respiratory diseases like asthma and idiopathic pulmonary fibrosis. Additionally, it demonstrates mitogenic effects on specific epithelial cells, implicating roles in mucosal homeostasis and regeneration.
Recombinant SCGB3A1 protein is typically produced using bacterial (E. coli) or mammalian expression systems, often incorporating tags (e.g., His-tag) for purification. The recombinant form retains native bioactivity, enabling functional studies in vitro and in vivo. Recent research explores its diagnostic potential as a biomarker for lung adenocarcinoma and preterm birth risk, while therapeutic applications focus on drug delivery strategies leveraging its inherent stability and tissue-targeting capabilities.
Despite progress, key questions remain regarding its receptor-mediated signaling pathways and tissue-specific isoform functions. Current investigations aim to elucidate interactions with proposed binding partners like HDGFRβ3 and evaluate clinical translatability in chronic inflammatory diseases and cancer.
×
